• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Adagio Medical Holdings Inc

    4/2/26 4:37:53 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care
    Get the next $ADGM alert in real time by email
    POS AM 1 tm2610719d2_posam.htm POS AM

     

    As filed with the United States Securities and Exchange Commission on April 2, 2026

    Registration No. 333-284266

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
     

    Washington, D.C. 20549

     

     

     

    POST-EFFECTIVE AMENDMENT NO. 2
    TO
     

    FORM S-1

    ON FORM S-3

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

     

     

    Adagio Medical Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of
    incorporation or organization)

    001-42199

    (Commission File Number)

    99-1151466

    (I.R.S. Employer Identification Number)

     

    26051 Merit Circle, Suite 102
    Laguna Hills, California 92653
    (949) 348-1188

    (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

     

     

     

    Todd Usen
    Chief Executive Officer
    26051 Merit Circle, Suite 102
    Laguna Hills, California 92653
    (949) 348-1188

    (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)

     

     

     

    Copies to:
    Eric Blanchard
    Paul Alexander
    Cooley LLP
    500 Boylston Street
    14th Floor
    Boston, MA 02116
    (617) 937-2300

     

    Approximate date of commencement of proposed sale to the public:

    From time to time after the effective date of this registration statement.

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ¨

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: x

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(c) under the Securities Act, check the following box. ¨

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer  ¨ Accelerated filer  ¨
       
    Non-accelerated filer  x Smaller reporting company  x
       
      Emerging growth company  x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Post-Effective Amendment No. 2 to the Registration Statement on Form S-1 on Form S-3 (File No. 333-284266) (“Post-Effective Amendment No. 2”) of Adagio Medical Holdings, Inc. is being filed solely to amend the Post-Effective Amendment No. 1 to the Registration Statement filed with the U.S. Securities and Exchange Commission on April 1, 2026, to correct Exhibit 23.4, the Consent of Independent Registered Public Accounting Firm. The original filing mistakenly included an unsigned version of the consent of WithumSmith+Brown, PC. No other changes have been made to the Registration Statement. This Post-Effective Amendment No. 2 does not modify any provision of the prospectus that forms part of the Registration Statement and, accordingly, the prospectus has not been included herein. This Post-Effective Amendment No. 2 is not intended to amend or delete any part of the Registration Statement except as specifically noted herein.

     

     

     

     

    PART II
    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 16. Exhibits

     

    Exhibit 
    Number
      Description  Schedule/
    Form
      File No.  Exhibit   Filing Date
    2.1†  Business Combination Agreement, dated as of February 13, 2024, by and among Aja HoldCo, Inc., ARYA Sciences Acquisition Corp IV, Aja Merger Sub 1, Aja Merger Sub 2, Inc. and Adagio Medical, Inc.  8-K  001- 42199  2.1   August 6, 2024
    2.2  Consent and Amendment No. 1 to the Business Combination Agreement, dated as of June 25, 2024, by and among ARYA Sciences Acquisition Corp IV and Adagio Medical, Inc.  8-K  001- 42199  2.2   August 6, 2024
    3.1  Amended and Restated Certificate of Incorporation of the Company.  8-K  001- 42199  3.1   August 6, 2024
    3.2   Amended and Restated By-Laws of the Company.  8-K  001- 42199  3.2   August 6, 2024
    4.1  Form of Base Warrant Agreement.  8-K  001- 42199  4.1   August 6, 2024
    4.2   Form of Pre-Funded Warrant Agreement.  8-K  001- 42199  4.2   August 6, 2024
    4.3   Form of Convert Warrant Agreement.  8-K  001- 42199  4.3   August 6, 2024
    4.4  Specimen Common Stock Certificate.  8-K  001- 42199  4.4   August 6, 2024
    5.1  Opinion of Reed Smith LLP.  S-1  333-284266  5.1    January 14, 2025
    10.1  Form of Convertible Security Subscription Agreement.   8-K  001- 42199  10.1    August 6, 2024
    10.2  Form of Adagio Holdings Stockholder Transaction Support Agreement.  8-K   001-42199  10.4    August 6, 2024
    10.3  Convert Guaranty, dated as of July 31, 2024, by and among Adagio Medical and the other parties thereto.   8-K  001- 42199  10.9    August 6, 2024
    10.4  Convert Security Document, dated as of July 31, 2024, by and among Adagio Holdings, Adagio Medical and the other parties thereto.  8-K   001- 42199  10.10    August 6, 2024
    10.5  Registration Rights Agreement dated as of July 31, 2024, by and among Adagio Medical, Perceptive Life Sciences Master Fund, Ltd. and the other parties thereto.  8-K   001- 42199  10.11    August 6, 2024
    10.6  Form of Adagio Holdings Convertible Note.   8-K  001- 42199  10.12    August 6, 2024
    10.7  Form of Non-Redemption Subscription Agreement.   8-K  001- 42199  10.13    August 6, 2024
    10.8  Form of Open Market Purchase Subscription Agreement.   8-K  001- 42199  10.14    August 6, 2024
    10.9  Form of Subscription Agreement with Pre-Funded Warrant and PIPE Warrant.  8-K   001- 42199  10.15    August 6, 2024
    10.10  PIPE Subscription Agreement, by and among the Perceptive PIPE Investor, Adagio and ARYA.  8-K   001- 42199  10.16    August 6, 2024

     

     

     

     

    Exhibit 
    Number
      Description  Schedule/
    Form
      File No.  Exhibit  Filing Date
    10.11  Amendment to PIPE Subscription Agreement, by and among the Perceptive PIPE Investor, Adagio and ARYA.  8-K  001- 42199  10.17  August 6, 2024
    10.12  Amended and Restated Subscription Agreement, by and among the Perceptive PIPE Investor, Adagio and ARYA.  8-K  001- 42199  10.18  August 6, 2024
    10.13  Form of Amended and Restated Subscription Agreement with Pre-Funded Warrant and Warrant.  8-K  001- 42199  10.19  August 6, 2024
    10.14  Form of Amended and Restated Open Market Purchase Subscription Agreement.  8-K  001- 42199  10.20  August 6, 2024
    10.15  Form of Amended and Restated Non-Redemption Subscription Agreement.  8-K  001- 42199  10.21  August 6, 2024
    10.16  2024 Bridge Financing Note Subscription Agreement, dated as of February 13, 2024, by and between ListCo, the Perceptive PIPE Investor and certain other investors thereto  8-K  001- 42199  10.22  August 6, 2024
    10.17  Form of Convert Waiver  8-K  001-42199  10.1  January 6, 2025
    23.1  Consent of Reed Smith LLP (included as part of Exhibit 5.1).  S-1  333-284266  5.1  January 14, 2025
    23.2*  Consent of WithumSmith+Brown, PC, independent registered public accounting firm for Adagio Medical Holdings, Inc.            
    24.1  Power of Attorney.  S-1  333-284266  24.1  January 14, 2025

     

    * Filed herewith. 

    † Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601. The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. 

    # Indicates a management contract or compensatory plan, contract or arrangement.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 2 to Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in Laguna Hills, California, on this 2nd day of April, 2026.

     

    ADAGIO MEDICAL HOLDINGS, INC.  
         
    By: /s/ Todd Usen  
      Name: Todd Usen  
      Title: Chief Financial Officer  

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

    Signature   Title   Date
             
    /s/ Todd Usen   Chief Executive Officer and Director   April 2, 2026
    Todd Usen   (Principal Executive Officer)    
             
    /s/ Deborah Kaster   Chief Financial Officer   April 2, 2026
    Deborah Kaster   (Principal Financial Officer and Principal Accounting Officer)    
             
    *   Director   April 2, 2026
    James L. Cox        
             
    *   Director   April 2, 2026
    Orly Mishan        
             
    *   Director   April 2, 2026
    Keyvan Mirsaeedi-Farahani        
             
    *   Director   April 2, 2026
    Timothy Moran        
             
    *   Director   April 2, 2026
    Sandra Gardiner        
             
    /s/ Todd Usen        
    Todd Usen        
    Attorney-in-fact        

     

     

    Get the next $ADGM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADGM

    DatePrice TargetRatingAnalyst
    12/2/2025$4.00Buy
    Lake Street
    More analyst ratings

    $ADGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adagio Medical Ultralow Temperature Ablation U.S. Pivotal Study Results to be Presented in Late-Breaking Session at Heart Rhythm Society 2026

    Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the pivotal results from the FULCRUM-VT study have been accepted for presentation in a late-breaking clinical science session at Heart Rhythm 2026 (HRS), the annual meeting of the Heart Rhythm Society. This is the first Investigational Device Exemption (IDE) study powered to evaluate the safety and effectiveness of Ultra-Low Temperature Ablation ("ULTA", formerly "ULTC") for the treatment of scar-related ventricular tachycardia (VT) in both ischemic and non-ischemic population. "Having FULCRUM-VT data

    4/1/26 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Reports Fourth Quarter and Full Year 2025 Results

    Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the fourth quarter ended December 31, 2025. Fourth Quarter and Recent Business Highlights: Announced the peer-reviewed publication in Circulation: Arrythmia and Electrophysiology, highlighting results from the U.S. Early Feasibility Study evaluating ultralow temperature cardiac ablation ("ULTA") for the treatment of scar-related ventricular tachycardia ("VT"), which demonstrated a favorable safety profile and no device- or procedure-related major adverse events in a real-world patie

    3/27/26 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Announces Publication of Pre-Clinical Results for Next Generation Ventricular Ablation Catheter

    Highlights Improvements in Next Generation ULTA Catheter, Including Potential 50-75% Reduction in Ablation Time Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of pre-clinical results of the Company's next generation ultra-low temperature ablation ("ULTA") technology designed to treat ventricular arrhythmias. The publication, which is titled "Initial Pre‐Clinical Evaluation of the Augmented Ultra‐Low Temperature Cryoablation Catheter for Ventricular Ablation" was published in the Journal of Cardiovascular Electrophysiology and describes s

    3/24/26 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    SEC Filings

    View All

    SEC Form S-8 POS filed by Adagio Medical Holdings Inc

    S-8 POS - Adagio Medical Holdings, Inc. (0002006986) (Filer)

    4/2/26 4:40:09 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form POS AM filed by Adagio Medical Holdings Inc

    POS AM - Adagio Medical Holdings, Inc. (0002006986) (Filer)

    4/2/26 4:37:53 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form POS AM filed by Adagio Medical Holdings Inc

    POS AM - Adagio Medical Holdings, Inc. (0002006986) (Filer)

    4/2/26 4:36:34 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Kaster Deborah bought $17,973 worth of shares (15,000 units at $1.20) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/18/25 6:00:11 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Usen Todd bought $225,973 worth of shares (207,315 units at $1.09) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/15/25 9:24:15 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Kaster Deborah

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    3/9/26 6:04:31 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Usen Todd

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    3/9/26 6:00:46 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Kaster Deborah bought $17,973 worth of shares (15,000 units at $1.20) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/18/25 6:00:11 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Leadership Updates

    Live Leadership Updates

    View All

    Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness

    Marie-Claude Jacques appointed Senior Vice President, Global Sales; Antwan Gipson joins as Senior Vice President, Manufacturing & Operations Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced two key additions to its senior leadership team: Marie-Claude Jacques as Senior Vice President, Global Sales and Antwan Gipson as Senior Vice President, Manufacturing and Operations. "These appointments represent a significant milestone as Adagio prepares for commercialization of our proprietary Ultra-Low Temperature Cardiac Ablation technology ("ULTC") for electrophys

    12/22/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors

    Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company's Audit Committee and Compensation Committee. Mr. Salmon, 60, recently retired from Medtronic after a distinguished, 20+ year tenure during which he held multiple senior global leadership roles across the company's cardiovascular and diabetes businesses. Most recently, he served as Executive Vice President and President of Medtronic's Cardiovascular Portfolio, which includes the Cardiac Rhythm, Cardiac Abl

    12/11/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Reports Third Quarter 2025 Results

    Continued Momentum Toward PMA Submission of ULTC Technologies Recent Financing Positions Company to Execute Growth Strategy Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of approximately $19 million expected to fund FDA submission activities and ongoing next generation catheter deve

    11/12/25 4:05:00 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Adagio Medical Holdings Inc

    SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    11/13/24 4:30:17 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Adagio Medical Holdings Inc

    SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    8/12/24 4:22:57 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Adagio Medical Holdings with a new price target

    Lake Street initiated coverage of Adagio Medical Holdings with a rating of Buy and set a new price target of $4.00

    12/2/25 8:38:52 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care